Dr. Dan Zabrowski has served as a director of Actuate Therapeutics since March 2021 and chairs its compensation committee. He has been a Venture Partner of Decheng Capital, a private investment firm, since July 2016. He previously spent more than 20 years at Roche in a range of global leadership roles, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit, and earlier held positions at Syntex, Fujisawa (now Astellas) and G.D. Searle. He has served on the boards of several public and private biotechnology companies, including Apexigen, BeyondSpring, Nimble Therapeutics and Endogena Therapeutics. Dr. Zabrowski earned a Ph.D. in Organic Chemistry from Indiana University, Bloomington, and a B.A. in Chemistry from Saint Louis University.